1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis
May 31, 2022 08:00 ET | Timber Pharmaceuticals
- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial - BASKING RIDGE, NJ, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber"...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021 17:58 ET | Timber Pharmaceuticals
BASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital Ichthyosis
March 15, 2021 08:30 ET | Timber Pharmaceuticals
- Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder  - Company Awarded Final Tranche of $1.5 Million FDA Orphan Products Clinical Trials...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 11, 2020 16:29 ET | Timber Pharmaceuticals
Virtual Presentation on Wednesday, September 16th at 12:30 PM ET WOODCLIFF LAKE, NJ, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire-- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”)...
1589917612572_5ec429193ef97e0004f1060c_logo.png
imber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 11, 2020 16:05 ET | Timber Pharmaceuticals
Virtual Presentation on Wednesday, September 16th at 12:30 PM ET WOODCLIFF LAKE, NJ, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”)...